Anti-B7-H3 Antibody (Omburtamab)

Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). B7-H3, also known as CD276. belongs to the B7 family, a group of structurally related cell surface protein ligands that bind to CD28 receptors on lymphocytes to regulate immune response. It is overexpressed in many cancers, acting as a negative regulator of T cell immune responses, thereby aiding in immune evasion. Its expression is associated with poor outcomes and survival times in patients. Through various studies, B7-H3 has been linked to other functions associated with tumor progression, such as angiogenesis, metastasis, and exosomal activity. B7-H3 can also be released in soluble form (sB7-H3) into the tumor microenvironment, where it has been implicated in increased migration and invasion of cancer cells. Due to its relative absence in normal tissues and its multifaceted effects on tumor cells, B7-H3 is an attractive target for immunotherapy treatments. One approach used are ADCs (antibody drug conjugates) and monoclonal antibodies. Omburtamab is a monoclonal antibody that was considered for the treatment of neuroblastoma, but further studies may be necessary to move it to approval.